LABORATORIOS FARMACEUTICOS ROVI, S.A. «12345...» Page 3 out of 18 02/04/2024 07:03 LABORATORIOS FARMACEUTICOS ROVI, S.A. Other relevant information The Company releases the press release related to the FDA’s approval of Risvan® (Risperidone ISM®) as a treatment for schizophrenia Register number: 27772 29/03/2024 09:32 LABORATORIOS FARMACEUTICOS ROVI, S.A. Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 22 March 2024 and 27 March 2024 Register number: 27758 22/03/2024 10:21 LABORATORIOS FARMACEUTICOS ROVI, S.A. Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 15 March 2024 and 21 March 2024 Register number: 27637 15/03/2024 10:17 LABORATORIOS FARMACEUTICOS ROVI, S.A. Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 8 March 2024 and 14 March 2024 Register number: 27476 12/03/2024 13:50 LABORATORIOS FARMACEUTICOS ROVI, S.A. Other relevant information ROVI informs of the agreement that has been concluded with Insud Pharma and Innvierte (CDTI) to incorporate, together with these two entities, a limited company engaged in the research and development of advanced therapies. Register number: 27397 08/03/2024 09:30 LABORATORIOS FARMACEUTICOS ROVI, S.A. Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 1 March 2024 y and 7 March 2024 Register number: 27325 07/03/2024 06:55 LABORATORIOS FARMACEUTICOS ROVI, S.A. On corporate transactions The Company notes the recent press speculation and informs about the assessment of potential strategic alternatives Register number: 27290 01/03/2024 11:02 LABORATORIOS FARMACEUTICOS ROVI, S.A. Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 23 February 2024 and 29 February 2024 Register number: 27239 27/02/2024 07:48 LABORATORIOS FARMACEUTICOS ROVI, S.A. Annual financial reports and audit reports La sociedad remite el Informe Financiero Anual del ejercicio 2023 Register number: 26768 27/02/2024 07:41 LABORATORIOS FARMACEUTICOS ROVI, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del segundo semestre de 2023 Register number: 26767 Page 3 out of 18 «12345...»